Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06135610 · ClinicalTrials.gov registry record
Social Determinants of Health in Patients With Penetrating Trauma Injuries Before and During the COVID-19 Pandemic
A clinical trial of COVID-19 and Social Determinants of Health, sponsored by Kern Medical Center.
- Completed
- Registry status
- 803
- Enrollment target
- 1
- Study location
NCT06135610: Completed study of COVID-19 and Social Determinants of Health, sponsored by Kern Medical Center.
NCT06135610 is a study of COVID-19 and Social Determinants of Health that has completed, run by Kern Medical Center. The registered enrollment target is 803 participants, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06135610, a study of COVID-19 and Social Determinants of Health, has completed, sponsored by Kern Medical Center.
- COMPLETED
- Registry status
- 803 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators report on the impact of the COVID-19 stay-at-home order concerning penetrating violence and its association within different socioeconomic regions within the county. The distribution and volume of violent offenses prior to the stay-at-home order was compared to during the stay-at-home order. This bears a crucial significance in our injury prevention and education efforts within our community.
Primary Outcome
Penetrating injury rate including gunshot wounds, stab wounds or other penetrating assult
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Postive SAR-CoV-2 PCR nasopharyngeal swab
Study Locations (1)
California
- Kern Medical Center - Bakersfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 803 participants |
| Start Date | 2019-03-01 |
| Est. Completion | 2021-02-01 |
What the finished NCT06135610 record still lists
NCT06135610 is an observational study that tracks outcomes without assigning an intervention. The registered 803 participants enrollment target is mid-sized for trials with a published cap, below the 38,462-participant average among 298 other COVID-19 trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which Postive SAR-CoV-2 PCR nasopharyngeal swab is the first listed.
NCT06135610 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06135610 about?
NCT06135610 is a clinical study titled "Social Determinants of Health in Patients With Penetrating Trauma Injuries Before and During the COVID-19 Pandemic". Investigators report on the impact of the COVID-19 stay-at-home order concerning penetrating violence and its association within different socioeconomic regions within the county. The distribution and volume of violent offenses prior to the stay-at-home order was compared to during the stay-at-home ...
What is the current status of trial NCT06135610?
This trial is currently completed. The enrollment target is 803 participants. The study started on 2019-03-01. Estimated completion is 2021-02-01.
What conditions does trial NCT06135610 study?
This clinical trial studies the following conditions: COVID-19, Social Determinants of Health, Penetrating Injury.
What interventions are being tested in trial NCT06135610?
The interventions under investigation include: Postive SAR-CoV-2 PCR nasopharyngeal swab (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06135610?
This trial is sponsored by Kern Medical Center, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06135610 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06135610's enrollment target sits among peer trials
803 89th of 298 higher than 210 of 298 other COVID-19 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
Cardiac Magnetic Resonance Tissue Characterization in COVID-19 Survivors
RECRUITING
-
COVID-19 Health Adjustments in Nutrition, General Wellness, and Exercise
RECRUITING
-
The Impact of COVID-19 on Maternal and Neonatal Outcomes
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04423211 · 804 participants · Phase 3
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
- NCT06522022 · 804 participants · NA
PTSD Screening in Pregnant Black Women
- NCT03524430 · 801 participants · NA
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
- NCT04613596 · 806 participants · Phase 2
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI